Posted by Michael Wonder on 07 Apr 2021
Hanmi's short bowel syndrome drug gets FDA fast track status
7 April 2021 - Hanmi Pharmaceutical said Wednesday that the U.S. Food and Drug Administration has granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912).
LAPS GLP-2 Analog is a new biopharmaceutical being developed for short-bowel syndrome with the company's platform technology, known as Labscovery.
